Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia

The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: A double blind study

“…The improvement in the muscle rigidity confirms the favorable profile of olanzapine in the treatment of schizophrenia (Tandon and Halbreich, 2003;Dossenbach et al, 2004). The opposite neuroendocrine effects of olanzapine and fluphenazine on plasma cortisol levels in schizophrenic patients (present study), and the "normalization" of the HPA axis hyperactivity (Muck-Seler et al, 1999;Ryan et al, 2004), support the assumption that the suppression of the HPA axis hyperactivity is related to the treatment response (Tandon and Halbreich, 2003).…”

“…Patients were part of the group included in a multicentric clinical trial (Dossenbach et al, 2004). The Positive and Negative Syndrome Scale (PANSS) (Kay et al, 1987) was used to evaluate schizophrenic symptoms, and baseline total PANSS scores were 96.9 ±15.4 for fluphenazine, and 107.7 ± 19.1 for olanzapine-treated patients, respectively.…”

“…Since olanzapine and fluphenazine differ in their side effects profile and clinical efficacy (Dossenbach et al, 2004), our hypothesis was that olanzapine and fluphenazine would differently affect plasma cortisol, PRL and muscle rigidity. The aim of the present study was to determine, in the smaller group of female schizophrenic patients extracted from the previous multicentric double blind study (Dossenbach et al, 2004), the effects of olanzapine or fluphenazine on plasma PRL and cortisol levels, and muscle rigidity after long term (22-weeks) treatment.…”

“…The aim of the present study was to determine, in the smaller group of female schizophrenic patients extracted from the previous multicentric double blind study (Dossenbach et al, 2004), the effects of olanzapine or fluphenazine on plasma PRL and cortisol levels, and muscle rigidity after long term (22-weeks) treatment.…”

Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 2: tratamento de longo prazo

“…Foram constatadas eficácia comparável nos sintomas positivos e superioridade nos sintomas negativos em comparação à risperidona (dose média de 7 mg/dia) , mas, em relação à sintomatologia negativa, esses dados não foram confirmados num estudo posterior de 12 semanas que utilizou uma dosagem inferior de risperidona (Conley e Mahmoud, 2001). Comparada à flufenazina, a olanzapina mostrou efeito superior nos sintomas positivos e na psicopatologia global (Dossenbach et al, 2004). Assim, conclui-se que há evidência convincente sobre a eficácia da olanzapina no tratamento de longo prazo (Nível A).…”